William Blair Brokers Increase Earnings Estimates for IQVIA

IQVIA Holdings Inc. (NYSE:IQV) – Research analysts at William Blair upped their Q4 2024 earnings per share estimates for IQVIA in a research note issued on Wednesday, December 11th. William Blair analyst M. Smock now anticipates that the medical research company will earn $2.83 per share for the quarter, up from their prior estimate of $2.82. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for IQVIA’s current full-year earnings is $10.18 per share. William Blair also issued estimates for IQVIA’s Q1 2025 earnings at $2.37 EPS.

Other equities analysts have also recently issued reports about the company. Redburn Atlantic assumed coverage on IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. Morgan Stanley lowered their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. JPMorgan Chase & Co. decreased their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Robert W. Baird dropped their price target on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a report on Wednesday, December 11th. Finally, Evercore ISI reduced their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $256.19.

IQVIA Stock Down 0.7 %

Shares of IQVIA stock opened at $199.06 on Monday. The company has a 50-day simple moving average of $212.24 and a two-hundred day simple moving average of $224.20. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market capitalization of $36.13 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 2.05 and a beta of 1.49.

Institutional Investors Weigh In On IQVIA

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Simplify Asset Management Inc. increased its stake in shares of IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Versor Investments LP bought a new position in IQVIA in the 3rd quarter worth $1,328,000. CIBC Asset Management Inc increased its stake in IQVIA by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock worth $62,501,000 after buying an additional 8,490 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in IQVIA by 17.5% during the third quarter. Sequoia Financial Advisors LLC now owns 75,054 shares of the medical research company’s stock valued at $17,785,000 after acquiring an additional 11,170 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in shares of IQVIA by 3.9% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,023,264 shares of the medical research company’s stock valued at $242,483,000 after acquiring an additional 38,307 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.